Qualitek Labs [QLL] vs Dr. Lal PathLabs [LALPATHLAB] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Qualitek Labs Ltd. wins in 7 metrics, Dr. Lal PathLabs Ltd. wins in 10 metrics, with 0 ties. Dr. Lal PathLabs Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Qualitek Labs Ltd. | Dr. Lal PathLabs Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 37.58 | 46.16 | Qualitek Labs Ltd. |
| Price-to-Book Ratio | 2.57 | 10.20 | Qualitek Labs Ltd. |
| Debt-to-Equity Ratio | 50.78 | 6.44 | Dr. Lal PathLabs Ltd. |
| PEG Ratio | N/A | -7.05 | N/A |
| EV/EBITDA | 26.91 | 32.00 | Qualitek Labs Ltd. |
| Profit Margin (TTM) | 8.97% | 19.84% | Dr. Lal PathLabs Ltd. |
| Operating Margin (TTM) | 15.25% | 20.79% | Dr. Lal PathLabs Ltd. |
| EBITDA Margin (TTM) | 15.25% | 20.79% | Dr. Lal PathLabs Ltd. |
| Return on Equity | 12.27% | 22.08% | Dr. Lal PathLabs Ltd. |
| Return on Assets (TTM) | 7.21% | 17.93% | Dr. Lal PathLabs Ltd. |
| Free Cash Flow (TTM) | $-128.53M | $5.15B | Dr. Lal PathLabs Ltd. |
| Dividend Yield | N/A | 1.56% | N/A |
| 1-Year Return | 41.19% | 15.37% | Qualitek Labs Ltd. |
| Price-to-Sales Ratio (TTM) | 5.12 | 9.15 | Qualitek Labs Ltd. |
| Enterprise Value | $4.38B | $228.83B | Dr. Lal PathLabs Ltd. |
| EV/Revenue Ratio | 6.24 | 8.59 | Qualitek Labs Ltd. |
| Gross Profit Margin (TTM) | N/A | 65.97% | N/A |
| Revenue per Share (TTM) | $79 | $160 | Dr. Lal PathLabs Ltd. |
| Earnings per Share (Diluted) | $9.58 | $31.61 | Dr. Lal PathLabs Ltd. |
| Beta (Stock Volatility) | -0.11 | 0.10 | Qualitek Labs Ltd. |
Qualitek Labs Ltd. vs Dr. Lal PathLabs Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Qualitek Labs Ltd. | -5.64% | -1.91% | 13.33% | 28.71% | 4.29% | 3.82% |
| Dr. Lal PathLabs Ltd. | 0.55% | -2.68% | -0.79% | 11.03% | 2.56% | 3.39% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Qualitek Labs Ltd. | 41.19% | 147.07% | 147.07% | 147.07% | 147.07% | 147.07% |
| Dr. Lal PathLabs Ltd. | 15.37% | 59.53% | 12.09% | 223.97% | 258.78% | 258.78% |
Performance & Financial Health Analysis: Qualitek Labs Ltd. vs Dr. Lal PathLabs Ltd.
| Metric | QLL | LALPATHLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.59B | ₹238.92B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 8,240 | 392,728 |
| 90 Day Avg. Volume | 7,253 | 321,187 |
| Last Close | ₹385.00 | ₹1,569.60 |
| 52 Week Range | ₹258.55 - ₹458.95 | ₹1,272.60 - ₹1,770.00 |
| % from 52W High | -16.11% | -11.32% |
| All-Time High | ₹458.95 (Sep 19, 2025) | ₹4,245.50 (Sep 13, 2021) |
| % from All-Time High | -16.11% | -63.03% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.11% |
| Quarterly Earnings Growth | N/A | -0.06% |
| Financial Health | ||
| Profit Margin (TTM) | 0.09% | 0.20% |
| Operating Margin (TTM) | 0.15% | 0.21% |
| Return on Equity (TTM) | 0.12% | 0.22% |
| Debt to Equity (MRQ) | 50.78 | 6.44 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹140.22 | ₹143.09 |
| Cash per Share (MRQ) | ₹0.46 | ₹77.96 |
| Operating Cash Flow (TTM) | ₹104.99M | ₹4.66B |
| Levered Free Cash Flow (TTM) | ₹-329,006,240 | ₹4.87B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.56% |
| Last 12-Month Dividend | N/A | ₹22.50 |
Valuation & Enterprise Metrics Analysis: Qualitek Labs Ltd. vs Dr. Lal PathLabs Ltd.
| Metric | QLL (Apr 26, 2026) | LALPATHLAB (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 37.58 | 46.16 |
| Forward P/E | N/A | 41.23 |
| PEG Ratio | N/A | -7.05 |
| Price to Sales (TTM) | 5.12 | 9.15 |
| Price to Book (MRQ) | 2.57 | 10.20 |
| Market Capitalization | ||
| Market Capitalization | ₹3.59B | ₹238.92B |
| Enterprise Value | ₹4.38B | ₹228.83B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.24 | 8.59 |
| Enterprise to EBITDA | 26.91 | 32.00 |
| Risk & Other Metrics | ||
| Beta | -0.11 | 0.10 |
| Book Value per Share (MRQ) | ₹140.22 | ₹143.09 |
Financial Statements Comparison: Qualitek Labs Ltd. vs Dr. Lal PathLabs Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | QLL (2025) | LALPATHLAB (2025) |
|---|---|---|
| Revenue/Sales | 702.27M | 24.61B |
| Cost of Goods Sold | 102.02M | 8.23B |
| COGS % of Revenue | 14.5% | 33.4% |
| Gross Profit | 600.25M | 16.38B |
| Gross Margin | 85.5% | 66.6% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 124.96M | 5.60B |
| Operating Margin | 17.8% | 22.8% |
| EBITDA | 170.94M | 7.74B |
| EBITDA Margin | 24.3% | 31.5% |
| Pre-Tax Income | 104.18M | 6.25B |
| Pre-Tax Income % of Revenue | 14.8% | 25.4% |
| Income Tax | 27.35M | 1.33B |
| Income Tax % of Revenue | 3.9% | 5.4% |
| Net Income (Profit) | 76.84M | 4.92B |
| Profit Margin | 10.9% | 20.0% |
Balance Sheet & Liquidity Metrics
| Metric | QLL (2025) | LALPATHLAB (2025) |
|---|---|---|
| Cash & Equivalents | 43.10M | 2.93B |
| Total Current Assets | 426.08M | 13.64B |
| Total Current Assets % of Revenue | 60.7% | 55.4% |
| Total Current Liabilities | 325.84M | 4.02B |
| Total Current Liabilities % of Revenue | 46.4% | 16.3% |
| Long-Term Debt | 308.61M | 1.03B |
| Long-Term Debt % of Revenue | 43.9% | 4.2% |
| Total Shareholders Equity | 927.82M | 22.06B |
| Retained Earnings | 145.04M | 18.60B |
| Retained Earnings % of Revenue | 20.7% | 75.6% |
| Property, Plant & Equipment | 589.98M | 3.36B |
Cash Flow Statement Comparison
| Metric | QLL (2025) | LALPATHLAB (2025) |
|---|---|---|
| Operating Cash Flow | 58.03M | 4.66B |
| Operating Cash Flow % of Revenue | 8.3% | 18.9% |
| Capital Expenditures | -233.17M | -436.20M |
| Free Cash Flow | -128.53M | 5.15B |
| FCF Margin | -18.3% | 20.9% |
| Debt Repayment | N/A | -833.34M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | QLL | LALPATHLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 9.98M | 166.97M |
| Float Shares | 3.60M | 75.55M |
| % Held by Insiders | 65.77% | 54.91% |
| % Held by Institutions | 0.00% | 31.54% |
| % Held by Public | 34.23% | 13.55% |
Dividend Analysis & Yield Comparison: Qualitek Labs Ltd. vs Dr. Lal PathLabs Ltd.
| Metric | QLL | LALPATHLAB |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹22.50 |
| Last 12-Month Dividend Yield | N/A | 1.56% |
| 3-Year Avg Annual Dividend | N/A | ₹23.50 |
| 3-Year Avg Dividend Yield | N/A | 0.51% |
| 3-Year Total Dividends | N/A | ₹70.50 |
| Ex-Dividend Date | N/A | Feb 05, 2026 |